Infectious Disease · 1987
Haemophilus influenzae type b (Hib) conjugate vaccine
Haemophilus influenzae type b conjugate vaccine
Before an effective vaccine existed, Haemophilus influenzae type b was the leading cause of bacterial meningitis in children under five in the United States, accounting for roughly 12,000 cases annually. Survivors often carried lasting deficits: sensorineural hearing loss occurred in approximately 15-20% of children who survived Hib meningitis, and other neurological sequelae including language delay and cognitive impairment were documented in a substantial fraction. Hib also caused epiglottitis, septic arthritis, osteomyelitis, and pneumonia, collectively representing around 20,000 cases of invasive disease per year in the United States alone.
A plain polysaccharide vaccine, based on the Hib capsular antigen polyribosylribitol phosphate (PRP), was licensed in the United States in 1985. It worked in children over two years old but failed in infants and toddlers below 18 months, precisely the age group with the highest burden of disease. The failure was immunological: T-cell-independent polysaccharide antigens do not generate memory B cells in young children, whose immune systems have not yet developed the infrastructure for that response. John Robbins and Rachel Schneerson at the NIH recognized that chemically conjugating the polysaccharide to a carrier protein would convert the immune response to T-cell dependent, generating both antibody and memory even in young infants.
The first conjugate product, PRP-D (PRP conjugated to diphtheria toxoid), received a license in the United States in 1987. Porter Anderson at the University of Rochester contributed critical conjugation chemistry for variants optimized for infant immunization schedules. Additional conjugates, including HbOC and PRP-OMP, were licensed by 1990 and proved effective in the primary infant series starting at two months of age. A Finnish field trial and subsequent U.S. data confirmed that the infant formulations generated protective antibody titers and significantly reduced invasive disease.
The reduction in disease burden was striking. From roughly 20,000 cases of invasive Hib disease per year in the United States in the pre-vaccine era, incidence fell by more than 99% in vaccinated populations by the mid-1990s. Hib meningitis, which had been a routine if feared diagnosis on pediatric wards, became rare enough that an entire generation of trainees would complete residency without seeing a case. Similar reductions occurred in other countries that introduced the vaccine into infant immunization programs.
The conjugation technology Robbins and Schneerson developed became the template for the next generation of vaccines against encapsulated bacteria. The 7-valent pneumococcal conjugate vaccine (Prevnar) was licensed in 2000, targeting the leading cause of bacterial meningitis in children after Hib was controlled. Meningococcal conjugate vaccines followed. Each of these products used the same principle: conjugate a pathogen's polysaccharide capsule to a protein carrier, convert the immune response from T-cell independent to T-cell dependent, and achieve protection in infancy. The Hib experience provided the proof of concept, the regulatory precedent, and much of the technical foundation for that entire vaccine lineage.
Key People
- John Robbins — NIH immunologist who pioneered Hib polysaccharide and conjugate vaccine development
- Rachel Schneerson — NIH biochemist who co-developed Hib conjugate vaccine technology with Robbins
- Porter Anderson — Rochester researcher who contributed key conjugation chemistry for infant Hib vaccines
- David Smith — Pediatric infectious disease specialist who co-led early Hib vaccine clinical trials
N Engl J Med, 1990 (infant efficacy field trial; first conjugate licensed 1987)
Related landmarks
- 1987 · AZT (Zidovudine) Trial for AIDS (Infectious Disease)
- 1984 · Marshall & Warren: Helicobacter pylori causes peptic ulcer disease (Infectious Disease)
- 1981 · First report of AIDS (Pneumocystis pneumonia cluster) (Infectious Disease)
- 1996 · Highly Active Antiretroviral Therapy (HAART) and the Vancouver protease-inhibitor combination era (Infectious Disease)